Singapore’s rapidly ageing population and growing burden of chronic diseases have created a new imperative for population health improvement. These challenges open new opportunities for policymakers and providers to source and scale payment and delivery innovations to fill key needs. For example, initiatives such as the new Health IT Master Plan (HITMAP) highlight how the path towards population health will depend on the capacity to collect, share, analyse, and act upon health and social data. This talk will provide a global perspective on policy, payment, and delivery innovations that hold promise to improve health and healthcare, and opportunities in Singapore to incorporate global lessons to transform the health system toward population health.
Data sources such as electronic health records and patient registries enable the development of real world evidence (RWE), which can inform decisions across the medical product lifecycle, including treatment decisions and those that impact care quality as well as payment and delivery. While the U.S. FDA has relied on RWE to support decision-making in specific contexts, there are further opportunities for RWE to further enhance the regulatory framework, especially regarding efficacy and benefit. CoRE invites you to join us for Professor Gregory Daniel’s seminar, which will: 1) provide an update on the current U.S. policy landscape with respect to RWE; 2) describe current efforts to support the enhanced development and use of RWE across a range of activities; and 3) stimulate discussion on how lessons from the U.S. context might inform existing efforts in Singapore.
APEC Life Science Innovation Forum Regulatory Harmonization Steering Committee Meeting. By Invitation only.
DIA and Duke-NUS Centre of Regulatory Excellence (CoRE) will host a 2-day conference in Singapore on accelerating access to health products to improve the response to pandemic diseases. Over these 2 days, we will discuss the global impact of infectious diseases and approaches to expedite research and product development (including vaccines and medical devices). We will also explore the pathways to accelerate patient access to innovative products and how to effectively manage a pandemic situation in Asia.
Of all the fields that Artificial Intelligence (AI) will disrupt in the coming years, the healthcare market may see the greatest paradigm shift. We will discuss current trends in AI development and investment in the healthcare sector, as well as the Food and Drugs Administration (FDA) regulatory hurdles that such technology may encounter.
As medical management moves beyond the traditional pills, tablets and injections, the arrival of new treatment modalities in the form of cells, tissues and gene therapies has gained the attention of many in the healthcare environment. While these products hold new promises and advances in medical sciences, they also pose new challenges and concerns across various stakeholders.
Every October, healthcare professionals look forward to attending the highly anticipated CoRE Scientific Event. This year’s event put the spotlight on the emerging topic of Real-World Evidence within the healthcare and regulatory spaces. With a turnout of over 250 participants from the healthcare industry, the symposium provided insightful presentations and rich discussions amongst thought leaders from CoRE’s Advisory Board and interested stakeholders on this important subject.
REGISTRATION IS NOW CLOSED. THANK YOU FOR YOUR OVERWHELMING SUPPORT. As medical treatment embraces the concept of precision medicines with the hope of optimising health outcomes, many are seeking to understand this new movement and how it may impact the current landscape. In particular, devices designed to complement the new therapies are often overlooked, even though such companion diagnostics are critical to the success of the precision medicines. This 1.5 day workshop provides the opportunity to hear from regulatory experts from major regulatory authorities and the industry, and participate in discussions on how to facilitate the accessibility of these trending healthcare products.
REGISTRATION IS NOW CLOSED. THANK YOU FOR YOUR OVERWHELMING SUPPORT. As medical treatment embraces the concept of precision medicines with the hope of optimising health outcomes, many are seeking to understand this new movement and how it may impact the current landscape. In particular, devices designed to complement the new therapies are often overlooked, even though such companion diagnostics are critical to the success of the precision medicines. This Seminar will give participants the opportunity to hear from regulatory experts from major regulatory authorities and the industry.
Advanced Therapies is a rapidly advancing field that offers exciting new therapeutic possibilities. To promote a better understanding of the frameworks and processes regulating cell and tissue therapies, this 2.5-day Workshop provides a platform for experts from regulatory authorities including the U.S. FDA, the European Medicines Agency, Japan’s PMDA and Korea’s MFDS to share their expertise and experience.